Withdrawing FDA approval of midodrine after marketing

JAMA. 2011 Feb 23;305(8):781-2; author reply 782. doi: 10.1001/jama.2011.161.
No abstract available

Publication types

  • Comment
  • Letter

MeSH terms

  • Adrenergic alpha-1 Receptor Agonists / adverse effects*
  • Clinical Trials as Topic
  • Disclosure
  • Drug Approval
  • Drug Industry
  • Midodrine / adverse effects*
  • Product Surveillance, Postmarketing / standards*
  • Safety-Based Drug Withdrawals*
  • Time Factors
  • United States
  • United States Food and Drug Administration

Substances

  • Adrenergic alpha-1 Receptor Agonists
  • Midodrine